贵州医科大学学报

2011, v.36;No.153(06) 589-591

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

匹多莫德口服液对急性加重期慢性阻塞性肺病患者细胞免疫的影响
Influence of Pidotimod Oral Liquid on T Lymphocyte Immunological Function of Patients with COPD in Acute Exacerbation Stage

马秀琴;陈如华;刘秀芳;
MA Xiuqin,CHEN Ruhua,LIU Xiufang (Department of Respiratory Disease,People's Hospital of Yixing City,Yixing 214200,Jiangsu,China)

摘要(Abstract):

目的:探讨匹多莫德口服液对慢性阻塞性肺病(COPD)急性发作期患者细胞免疫功能的影响。方法:将COPD急性发作期患者60例分为治疗组和对照组各30例,另选30例体检的健康老年人为正常对照组;对照组给予祛痰、平喘、抗炎、给氧常规治疗,治疗组除常规治疗外给予匹多莫德口服液,每天2次,每次0.4 g,疗程14 d,比较两组治疗后的临床疗效,同时检测治疗前后T细胞亚群的变化。结果:治疗组总有效率为96.7%,对照组为83.3%,治疗组优于对照组(P<0.05);两组COPD患者治疗前T细胞亚群CD+3、CD+4、CD+4/CD+8水平显著低于正常对照组,P<0.01;治疗组治疗后CD+3、CD+4、CD+4/CD+8均明显增加,与治疗前及治疗后对照组比较差异有显著性(P<0.05);对照组治疗前后CD+3、CD+4、CD+4/CD+8,差异无显著性(P>0.05)。结论:匹多莫德口服液可调理COPD急性发作期患者的T淋巴细胞免疫功能,明显改善患者的临床症状。
Objective: To study the influences of pidotimod on T lymphocyte immunological function of patients with chronic obstructive pulmonary disease(COPD) in acute stage.Methods: Sixty patients with COPD in acute stage were randomly divided into treatment group(group T) and control group(group C),and thirty healthy people were selected as healthy group(group H).Group C accepted expectorant,anti-asthma,anti-inflammatory and oxygen therapies.Beside of conventional therapy,Group T was given pidotimod oral liquid 0.4 twice a day for 14 days.The clinical effects of the two groups after treatment were compared.Meanwhile,the changes of T cell subgroups were detected before and after treatment.Results: The total effective rate of group T was 96.7% and that of group C was 83.3%,which showed a notable difference between the two groups(P<0.05).The levels of CD+3,CD+4 and CD+4/CD+8 in two diseased groups were significantly lower than those in group H(P<0.01).After treatment,the levels of CD+3,CD+4 and CD+4/CD+8 in group T were obviously higher than those before treatment and those in group C(P<0.05).However,there was no significant difference of the above indexes in group C before and after treatment(P>0.05).Conclusions: Pidotimod could regulate T lymphocyte immunological function of patients with COPD in acute stage and obviously improve their clinical symptoms.

关键词(KeyWords): 匹多莫德;肺疾病,慢性阻塞性;免疫,细胞
pidotimod;pulmonary disease,chronic obstructive;immunity cellular

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 马秀琴;陈如华;刘秀芳;
MA Xiuqin,CHEN Ruhua,LIU Xiufang (Department of Respiratory Disease,People's Hospital of Yixing City,Yixing 214200,Jiangsu,China)

Email:

DOI: 10.19367/j.cnki.1000-2707.2011.06.013

文章评论(Comment):

序号(No.) 时间(Time) 反馈人(User) 邮箱(Email) 标题(Title) 内容(Content)
反馈人(User) 邮箱地址(Email)
反馈标题(Title)
反馈内容(Content)
扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享